静脉内至皮下注射促红细胞生成素 α 转换的成本分析。
Cost analysis of an intravenous to subcutaneous epoetin α conversion.
机构信息
Manitoba Renal Program, Winnipeg, Man., Canada.
出版信息
Am J Nephrol. 2013;38(6):496-500. doi: 10.1159/000357052. Epub 2013 Dec 11.
BACKGROUND/AIMS: A cost analysis of a conversion from intravenous (IV) to subcutaneous (SC) epoetin α in patients receiving chronic in-center hemodialysis (HD).
METHODS
This retrospective analysis compared epoetin α drug costs during a 6-month period of IV usage (July to December 2010, period 1) to a 6-month period of SC usage (July to December 2011, period 2) in four large in-center HD units. Data were collected from quarterly counts of HD patients receiving epoetin α and monthly inventory billing records.
RESULTS
622 HD patients who received IV epoetin α (period 1) were compared to 609 HD patients who received SC epoetin α (period 2). A 12.6% decrease in dose was observed. The average weekly cost of epoetin α was USD 173.02 per patient during the IV period versus USD 151.20 per patient during the SC period. This equated to a yearly cost savings of USD 1,135 per patient with SC epoetin α.
CONCLUSION
The switch from IV to SC epoetin α was successfully implemented in all four centers and realized significant cost savings.
背景/目的：对接受中心慢性血液透析（HD）的患者，将静脉内（IV）注射用促红细胞生成素α转换为皮下（SC）注射用促红细胞生成素α的成本分析。
方法
这项回顾性分析比较了四个大型中心 HD 单元中 IV 使用（2010 年 7 月至 12 月，第 1 期）6 个月与 SC 使用（2011 年 7 月至 12 月，第 2 期）6 个月期间的促红细胞生成素α药物成本。数据来自接受促红细胞生成素α治疗的 HD 患者每季度的计数和每月的库存计费记录。
结果
622 名接受 IV 注射用促红细胞生成素α（第 1 期）的 HD 患者与 609 名接受 SC 注射用促红细胞生成素α（第 2 期）的 HD 患者进行了比较。观察到剂量减少了 12.6%。IV 期每个患者每周的促红细胞生成素α平均费用为 173.02 美元，而 SC 期每个患者为 151.20 美元。这相当于每个患者使用 SC 注射用促红细胞生成素α可节省 1135 美元的年成本。
结论
在所有四个中心都成功实施了从 IV 到 SC 注射用促红细胞生成素α的转换，并实现了显著的成本节约。
Zotero 插件